ADMA

ADMA BIOLOGICS INC

Health Care·Biotechnology·$2.6B

Reported·Q3-2019

ADMA Biologics Misses on EPS, Stock Down 3.11%

Metric	Actual	Expected	Surprise
EPS	$-0.19	N/A	N/A
Revenue	N/A	N/A	N/A

management commentary, guidance changes, and full analysis available with Pro.

More Earnings This Week

OReported

REALTY INCOME CORP REIT

Nov 4, 2019

UBERReported

UBER TECHNOLOGIES IN

Nov 4, 2019

MARReported

MARRIOTT INTL INC NE Class A

Nov 4, 2019

OXYReported

OCCIDENTAL PETE CORP

Nov 4, 2019

Management Commentary

Tone: Defensive

Management expressed a cautious approach regarding future performance. They emphasized the importance of operational efficiency.

Management did not provide specific revenue figures or guidance for the upcoming quarters.

The company is focusing on operational improvements and cost management.

What It Means

ADMA Biologics reported a loss per share of $0.19, but did not disclose revenue figures. The stock fell by 3.11% following the report, likely due to the lack of guidance and clarity on financial performance. Investors may be concerned about the company's future prospects without specific targets or revenue updates.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime